DKSH and Merdury Biopharmaceutical Corporation have entered into a partnership to supply Merdury’s Metformin to the Vietnamese market. The product will be distributed by local distribution partners after importation.
Ho Chi Minh City, August 9, 2023 – DKSH, a leading Market Expansion Services Provider, has successfully signed a Memorandum of Understanding (MoU) with Merdury Biopharmaceutical Corporation (Merdury) to bring Metformin, a rapid-acting treatment for type 2 diabetes, to Vietnam.
With broad industry knowledge, in-depth market insight, and a strong network, DKSH will support Merdury with procedures to access the market. Once imported, the product will then be distributed by local distribution partners.
Founded in July 2019, Merdury focuses on the development of drugs for unmet medical needs. With its proprietary StackDose™ platform, which is developed based on a 3D powder printing technology and process, and a unique drug binding formula, Merdury develops new tablet dosage forms with controlled time dissolution and precise site absorption. Drugs manufactured by Merdury also improve the bioavailability of active pharmaceutical ingredients (APIs) to optimize their effects, thereby reducing the dosage of drugs used and thus reducing side effects.
Edward Lin, Chairman of Merdury Biopharmaceutical shared at the signing ceremony: “Vietnam is one of our key markets as we aim to expand our presence outside Taiwan with our advanced diabetes treatment. We highly value DKSH’s expertise and its capillary network of partners in Vietnam, which we believe, is strategic to our future growth in this exciting market.”
Phillip Wray, General Director, DKSH Pharma Vietnam, stated: “This MoU marks the first important step on our shared journey of bringing rapid-acting treatment for type 2 diabetes to the Vietnamese market. We are excited to be Merdury’s trusted partner, and we are thrilled that diabetes patients in Vietnam will soon have better access to more treatment options.”